SUMMARY The postprandial contractions of the gall bladder result from the interaction of neurohormonal factors but their relative contribution is unknown. This study was designed to determine the role of cholecystokinin (CCK) in gall bladder contractions using a highly selective and potent CCK-receptor antagonist, CR-1505 (loxiglumide) in healthy men either infused with exogenous CCK in graded doses (1P56-50 pmollkg/h) or subjected to modified sham feeding (MSF) and ordinary feeding tests. The gall bladder volume measured by real time ultrasonography showed dose dependent decrease in the gall bladder volume in 10 subjects when CCK8 was infused iv in graded doses reaching about 15% at 1.56 pmol/kg/h and 91% at 50 pmollkg/h. Close correlation between the decrease in gall bladder volume and the dosage of CCK or the increments in plasma CCK-bioactivity was observed. After pretreatment with loxiglumide, CCK resulted in similar increments in plasma CCK-bioactivity but failed to affect the gall bladder volume at CCK doses up to 6.25 pmol/kg/h and caused only 53% reduction at 50 pmollkg/h. Modified sham feeding and real feeding reduced the volume of gall bladder by 20% and 70%, respectively and loxiglumide decreased these values to 15% and 30%, respectively. This study provides evidence that loxiglumide is highly potent and selective CCK antagonist and that endogenous CCK plays an important role both in the postprandial contractions of gall bladder.
Since 1928 when Ivy and Oldberg' discovered that cholecystokinin (CCK), present in the extracts of canine intestinal mucosa, stimulated the contractions of gall bladder, numerous studies have provided evidence that CCK is the major factor responsible for the gall bladder emptying in animals and in men under various physiological conditions.2
In recent years, the non-invasive techniques such as real time ultrasonography have been used to quantify the gall bladder emptying'4 and sensitive assays have been developed`7 to measure physiological alterations in plasma concentrations of CCK. With these methods, the dynamics of gall bladder emptying have been characterised and strong evidence supporting a causal relationship between plasma CCK concentrations and gall bladder con-tractions has been shown.4 As originally proposed by Ivy and Oldberg' postprandial gall bladder emptying occurs mainly as the result of CCK-induced gall bladder contractions.
Gall bladder contractions also occur, however, during vagal cholinergic stimulation`and after feeding when the plasma CCK concentrations either remain low or are only moderately raised.' The mechanism of these contractions and the possible involvement of CCK in postprandial conditions remains uncertain. The assessment of the contribution of CCK has been now possible because of recent description of highly specific and potent CCKreceptor antagonists""' which allow the gall bladder contractions to be measured in the absence of the effect of CCK. This study was undertaken to clarify the role of CCK in the gall bladder contractions during the interdigestive period, after administration of 1136 exogenous CCK and after sham feeding or ordinary feeding using CR 1505 (loxiglumide), a potent and highly effective CCK-receptor antagonist."
Methods

SUBJECTS
Studies were carried out on 20 young healthy male subjects (mean age 24 years, range 18- Plasma gastrin and polypeptide were measured by specific radioimmunoassays as described. 12 Figure 2 . All increments in plasma CCK concentrations occurring during CCK infusion resulted in a significant reduction in the gall bladder volume. About 50% Previous studies' 49 using real time ultrasonography of the gall bladder showed that this is an easy and reliable method to quantify gall bladder contractions and that the assessment of the reduction in gall bladder volume may serve as a highly sensitive method of detection of increments in plasma concentrations of CCK. 4 The threshold for stimulating of gall bladder contractions was the increment in plasma immunoreactive CCK by 1.3 pM when a dose of 0.8 pmol/kg/h CCK was administered.4 A highly significant correlation was found between the decreases in gall bladder volume and the dosage of infused CCK or the increment in plasma CCK concentrations. Our study fully confirmed the usefulness of serial ultrasonography in detecting minute alterations in the dosage of CCK or in the plasma concentrations of this hormone. Cholecystokinin at a dose of 156 pmol/ kg/h, that raised plasma CCK bioactivity by about 1 0 pM, caused a significant reduction (by about 15%) in gall bladder volume. Further increase in the dosage of infused CCK or in the plasma CCK-bioactivity resulted in a gradual decrease in gall bladder volume reaching at a dose of 50 pmol/kg/h of CCK about 91 % of the initial value.
The major finding of this study is that oral pretreatment with loxiglumide abolished the gall bladder motor responses to CCK at lower doses and greatly reduced those at higher doses of CCK. In loxiglumide treated subjects the threshold dose of exogenous CCK, that caused a significant diminution in the gall bladder volume, was 6*25 pmol/kg/h -that is. about four times higher than in tests without loxiglumide. The dose of infused CCK and the increment in plasma CCK-bioactivity producing 50% reduction in gall bladder volume were four to six times higher in loxiglumide treated subjects than in untreated placebo controls. This indicates that loxiglumide greatly reduced the sensitivity of CCK receptors in the gall bladder muscle to the agonist. As loxiglumide reduced both the maximal gall bladder response to CCK and significantly increased the dose of the agonist producing 50% reduction in gall bladder volume, loxiglumide functions in vi1'o, unlike in vitro,'' as mixed type CCK-receptor antagonist.
It is of interest that in dogs, proglumide used in a massive dose (300 mg/kg/h) not only abolished the gall bladder contraction caused by intra-duodenal Lipomul, a potent releaser of endogenous CCK but also increased the basal gall bladder volume.'4 Although this effect has been attributed to increased hepatic bile production by proglumide, it could also result from the removal by this CCK-antagonist of basal CCK background stimulation of the gall bladder motor 'tone'. Proglumide has relatively low potency as CCK antagonist, while loxiglumide, a proglumide analogue obtained by altering the structure of dialkyl amide and by addition of benzoyl moiety"" exhibits over 1000 times higher CCK antagonistic activity than proglumide. It appears to be active after parenteral and oral administration and because of good tolerance and no toxicity' it has been considered for diagnostic and therapeutic uses in disorders of the motility of biliary tract. As with proglumide in animals,'4 loxiglumide in our subjects increased the volume of the unstimulated gall bladder suggesting that circulating CCK in fasted humans displays a tonic influence on the gall bladder smooth muscle.
Our finding that loxiglumide is a highly effective CCK antagonist prompted our subsequent studies designed to determine the role of CCK in gall bladder contractions elicited by cephalic-vagal stimulation and by ordinary feeding. Cephalic vagal stimulation was induced by the 'chew and spit' technique, which is known and confirmed by this study to evoke a potent gastric acid secretion.'2 Such modified sham feeding (MSF) was found previously to induce about 30% reduction in the gall bladder volume`but in that report gastric acid was not aspirated so that it could enter the duodenum and release endogenous CCK.' This CCK release, even undetected by radioimmunoassay, could enhance the vagally induced contraction of gall bladder. According to our data, modified sham feeding does reduce significantly the gall bladder volume even in subjects with aspirated gastric acid but the reduction is relatively smaller (about 20%) than reported before' possibly because of the aspiration of gastric acid and the prevention of release of CCK by endogenous duodenal acidification.
The mechanism of the small but significant reduction by modified sham feeding in the gall bladder volume is unclear but previous study of Hopman et This study also attempted to determine the role of CCK in the postprandial contraction of gall bladder. Feeding of fat and protein rich meal resulted in about 70% reduction in gall bladder. The blockade of CCK receptors by loxiglumide was followed by only 30% reduction in gall bladder volume. This indicates that CCK is the major but not the only factor responsible for the postprandial decrease in gall bladder volume. This is supported by the increment in plasma CCK bioactivity by 3-7 pM but such CCK increment alone such as induced by exogenous CCK should cause much smaller decrease in the gall bladder volume than that observed postprandially. This indicates that in addition to CCK, other factors, particularly vagalcholinergic stimulation elicited by neural reflexes activated by feeding, may contribute to the postprandial decrease in the gall bladder volume. ' " Cholecystokinin infused exogenously or released endogenously is known to stimulate the release of polypeptide.'1 Indeed, graded doses of CCK produced gradual increase in plasma polypeptide concentrations. This effect appears to be mediated by CCK receptors as loxiglumide was highly effective in the reduction in plasma polypeptide response to infused CCK. Similarly, plasma polypeptide rose after feeding possibly due to the action of endogenous CCK but the postprandial increment in plasma polypeptide was several times greater than that achieved with exogenous CCK producing equal rate increase in plasma CCK and was only partly attenuated by loxiglumide. This could be interpreted that polypeptide-releasing cells are sensitive to a variety of other than CCK stimulants, particularly to vagal-cholinergic input, and that CCK is only a minor factor in the postprandial release of polypeptide. As polypeptide was reported to relax the gall bladder"' it is possible that highly raised plasma polypeptide after a meal in both loxiglumide treated and untreated subjects could counteract, at least in part, the effects of endogenous CCK and other stimulants of the gall bladder motility. This could contribute to relatively smaller effect of endogenous stimulants on gall bladder contraction in the postprandial state as compared with that induced by exogenous hormone when plasma increments in polypeptide concentrations were less marked. This study was supported in part by research grant CPBP -06.03.3.6. 
